Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for migraine
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Rimegepant (Nurtec ODT) - To treat migraine Drug Approval Package: NURTEC ODT NURTEC ODT " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NURTEC ODT Company: Biohaven Pharmaceuticals Application Number: 212728 Approval Date: 02/27/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF
Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. To assess the efficacy of manual acupuncture as prophylactic treatment for acupuncture naive patients with episodic migraine without aura.Multicentre, randomised, controlled clinical trial with blinded participants, outcome assessment, and statistician.Seven hospitals in China, 5 June 2016 to 15 November 2018.150 acupuncture naive patients (...) with episodic migraine without aura.20 sessions of manual acupuncture at true acupuncture points plus usual care, 20 sessions of non-penetrating sham acupuncture at heterosegmental non-acupuncture points plus usual care, or usual care alone over 8 weeks.Change in migraine days and migraine attacks per four weeks during weeks 1-20 after randomisation compared with baseline (four weeks before randomisation).Among 150 randomised patients (mean age 36.5 (SD 11.4) years; 123 (82%) women), 147 were included
Ubrogepant (Ubrelvy) - acute treatment of migraine with or without aura in adults Drug Approval Package: UBRELVY UBRELVY " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: UBRELVY Company: Allergan Sales, Inc. Application Number: 211765 Approval Date: 12/23/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files
Fremanezumab (Ajovy) - chronic and episodic migraine 1 Published 13 January 2020 1 SMC2226 fremanezumab 225mg solution for injection in pre- filled syringe (Ajovy®) Teva UK Limited 6 December 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission fremanezumab (Ajovy ® ) is accepted (...) for restricted use within NHSScotland. Indication under review: For prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments. Three phase III studies demonstrated superiority of fremanezumab over placebo in reducing the number of monthly migraine days in patients with chronic and episodic migraine. This advice applies only
Galcanezumab (Emgality) - migraine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012 will be updated
Ubrogepant for the Treatment of Migraine. Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant. We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack (...) , with the option to take a second dose. The coprimary efficacy end points were freedom from pain at 2 hours after the initial dose and absence of the most bothersome migraine-associated symptom at 2 hours. Secondary end points included pain relief (at 2 hours), sustained pain relief (from 2 to 24 hours), sustained freedom from pain (from 2 to 24 hours), and absence of symptoms associated with migraine (photophobia, phonophobia, and nausea) at 2 hours.A total of 1672 participants were enrolled; 559 were
Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.7 of the dossier assessment Galcanezumab (Migräne) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 June 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-28 Galcanezumab (migraine (...) ) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-28 Version 1.0 Galcanezumab (migraine) 27 June 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Galcanezumab (migraine) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 March 2019 Internal Commission No.: A19-28 Address
Lasmiditan (Reyvow) - For the acute treatment of migraine with or without aura, in adults Drug Approval Package: REYVOW (lasmitidan) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: REYVOW (lasmitidan) Company: Eli Lilly Application Number: 211280 Orig 1 Approval Date: 10/11/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. Ubrogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acute treatment of migraine.To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack.Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack (...) , clinical trial (ACHIEVE II) conducted in the United States (99 primary care and research clinics; August 26, 2016-February 26, 2018). Participants were adults with migraine with or without aura experiencing 2 to 8 migraine attacks per month.Ubrogepant 50 mg (n = 562), ubrogepant 25 mg (n = 561), or placebo (n = 563) for a migraine attack of moderate or severe pain intensity.Co-primary efficacy outcomes were pain freedom and absence of the participant-designated most bothersome migraine-associated
Targeting calcitonin gene-related peptide: a new era in migraine therapy. Migraine is one of the most prevalent and disabling diseases worldwide, but until recently, few migraine-specific therapies had been developed. Extensive basic and clinical scientific investigation has provided strong evidence that the neuropeptide calcitonin gene-related peptide (CGRP) has a key role in migraine. This evidence led to the development of small molecule CGRP receptor antagonists and monoclonal antibodies (...) targeting either CGRP or its receptor. Clinical trials investigating these therapies have consistently shown statistically significant efficacy for either the acute or preventive treatment of migraine. No serious safety or tolerability issues have been identified in the trials of the monoclonal antibody therapies. Although the appropriate place of these new migraine-specific therapies relative to other available acute and preventive treatments remains to be determined, a growing body of evidence shows
Erenumab (Aimovig) - Migraine erenumab | CADTH.ca Find the information you need erenumab erenumab Last Updated: October 3, 2019 Result type: Reports Project Number: SR0578-000 Product Line: Generic Name: erenumab Brand Name: Aimovig Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Migraine Manufacturer Requested Reimbursement Criteria 1 : For prevention of migraine in adults who have at least 8 migraine days per month and who have previously failed, are intolerant, or have (...) a contraindication to at least two migraine preventive therapies Submission Type: New Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable. Key Milestones 2 Call for patient input posted April 04, 2019 Clarification: CADTH initially posted the call for patient from July 12, 2018 to August 31
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and tolerability of fremanezumab, a fully humanised CGRP antibody, in patients with migraine who had previously (...) not responded to two to four classes of migraine preventive medications.The randomised, double-blind, placebo-controlled, parallel-group, phase 3b FOCUS trial was done at 104 sites (including hospitals, medical centres, research institutes, and group practice clinics) across Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, the UK, and the USA. We enrolled participants aged 18-70 years with episodic or chronic migraine who had
2019LancetControlled trial quality: predicted high